Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma. by Liu, Pei et al.
UCLA
UCLA Previously Published Works
Title



















eScholarship.org Powered by the California Digital Library
University of California
1Scientific RepoRts | 7: 1580  | DOI:10.1038/s41598-017-01763-8
www.nature.com/scientificreports
Wnt inhibitory factor 1 (WIF1) 
methylation and its association 
with clinical prognosis in patients 
with chondrosarcoma
Pei Liu1,2, Jacson K. Shen1, Francis J. Hornicek1, Fuyun Liu2 & Zhenfeng Duan1
Chondrosarcoma (CS) is a rare cancer, but it is the second most common primary malignant bone tumor 
and highly resistant to conventional chemotherapy and radiotherapy. Aberrant DNA methylation 
in the promoter CpG island of Wnt inhibitory factor 1 (WIF1) has been observed in different cancers. 
However, no studies have shown the relationship between WIF1 methylation and CS. In this study, we 
found promoter methylated WIF1 in both CS cell lines (CS-1 and SW1353) and tumor tissues. Western 
blot analysis confirmed loss WIF1 expression and activation of Wnt pathway proteins (Wnt5a/b, LRP6, 
and Dvl2). We subsequently examined the correlation between levels of WIF1 methylation and overall 
survival (OS) and progression-free survival (PFS) in CS patient samples with a follow-up spanning 234 
months (mean: 57.6 months). Kaplan-Meier survival curves and log-rank tests revealed that high levels 
of WIF1 methylation were associated with lower OS and PFS rates (p < 0.05). Multivariate Cox hazard 
analysis suggested that detection of high level methylation of WIF1 could be an independent prognostic 
factor in OS and PFS. In conclusion, we found that WIF1 is epigenetically silenced via promoter DNA 
methylation in CS and propose that WIF1 methylation may serve as a potential prognostic marker for 
patients with CS.
Chondrosarcoma (CS) is a heterogeneous subtype of malignant cartilage forming tumor. It is a rare cancer in 
humans and is diagnosed in approximately 600 patients per year in the United States. CS is the second most 
common primary bone cancer after osteosarcoma1, 2. CS accounts for more than 20% of all primary bone malig-
nancies and affects people at any age with a predilection for proximal femur and pelvic sites3–5. Pathological 
identification and radiographic imaging remain important diagnostic tools in the clinical management of patients 
with CS. However, the reliability of diagnosis by the current subjective imaging and histological criteria has been 
controversial6. CS, especially conventional CS, is notoriously resistant to both chemotherapy and radiation treat-
ment7. Thus, surgical resection remains the primary treatment for localized lesions and radiotherapy is limited 
to the definitive treatment of inoperable micro-lesions and in the palliation of local symptoms6. The outcome of 
patients with CS is relatively poor largely due to the potent capacity for local invasion and distant metastasis8, 9. 
Five-year survival rates of patients with dedifferentiated CS are less than 20% as a result of early disseminated 
metastases6, 10–12. Therefore, there is an urgent need to develop novel strategies for diagnosis, treatment, and prog-
nosis of CS to improve outcomes for patients.
Recently, aberrant DNA methylation and epigenetic changes have been found to play a pivotal role in the 
pathogenesis of human malignancies. Hypermethylation mostly presents at the promoter CpG island of 
tumor suppressor genes and inactivates gene expression, while hypomethylation commonly affects repet-
itive DNA sequences and/or gene regulatory regions13. Accumulating data has shown that DNA methylation 
of tumor-related genes may serve as biomarkers to indicate the diagnosis and/or prognosis of human cancers, 
including CS14. For example, methylation of tumor suppressor gene Runt-related transcription factor 3 (RUNX3) 
has been reported as a potential prognostic indicator for CS15, 16. Recently, methylation of Wnt inhibitory factor 1 
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(WIF1) has also been found in different cancers, including in lung cancer, gastric cancer, and osteosarcoma17–21. 
However, no studies have shown the relationship between WIF1 methylation and CS.
WIF1 is a lipid-binding protein coding gene that binds to Wnt proteins, preventing them from passing signals 
to the cell. WIF1 is believed to function as a tumor suppressor gene by disrupting Wnt signaling, including the 
Wnt canonical pathway that regulates gene transcription, and could activate various downstream oncogenes. 
Wnt proteins comprise a large family of secreted cysteine-rich glycoproteins and have been found to play critical 
roles in the development and progression of human cancers22, 23. Each member of the Wnt family is defined by its 
amino acid sequence rather than the functions of its protein. Wnt has been associated with a number of different 
activities and downstream signaling pathways. The majority of effort in this field of cancer research has been 
focused on β-catenin or canonical-dependent Wnt signaling. Normally, Wnt ligands bind to the frizzled and 
low-density lipoprotein receptor related protein-5/6 (LRP-5/6) and subsequently activate the intracellular protein, 
Dishevelled (Dvl). Activated Dvl leads to the repression of glycogen synthase kinase 3β (GSK-3β), resulting in the 
disruption of the multi-protein complex, which is involved in the degradation of β-catenin. This complex is com-
prised of GSK-3β, adenomatous polyposis coli (APC), and axin23. Hence, β-catenin accumulates in the cytoplasm 
and translocates to the nucleus, where in cooperation with members of the T cell factor/lymphoid enhancer factor 
(TCF/LEF) family, subsequently activates several oncogenes, including c-Myc, cyclin D1, metalloproteinases, 
and c-Met21, 23. Nevertheless, Wnt antagonists, including WIF1, are able to collapse this pathway by inhibiting 
the binding of Wnt ligands to receptor complexes, followed by β-catenin phosphorylation and degradation, and 
finally blocking the TCF/LEF transcription of a wide range of oncogenes, thus preventing tumorogenesis21, 23. 
Dysregulation of Wnt signaling has been observed in various bone malignancies, including osteosarcoma, Ewing 
sarcoma, and CS20, 21, 24–28. Wnt signaling is tightly regulated by either directly binding with Wnt ligands, WIF1, 
or indirectly binding to Wnt receptors, such as Dickkopf (Dkk) family proteins21. Elevated DKK levels have been 
found to be significantly correlated with the expression of β-catenin in CS29. Targeting the Wnt/β-catenin path-
way has been proposed as a potential therapeutic treatment for sarcoma. However, the relationship between the 
epigenetic status of WIF1 and the activation and expression of Wnt in CS is unknown.
In this study, our primary aim was to assess the status of WIF1 DNA methylation in CS and to further exam-
ine the correlation between levels of WIF1 methylation and clinical prognosis of CS. Protein expression levels 
of WIF1 and members of the Wnt family were also measured to assess the potential tumor suppressor role of 
methylated WIF1 in the Wnt pathway in CS.
Materials and Methods
Cell lines and cell culture. The human CS cell line SW1353 was purchased from American Type Tissue 
Collection (Rockville, MD). The human CS cell line CS-1 was established in our laboratory as previously 
reported30–32. These two cell lines were cultured in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal 
bovine serum, 100 units/ml penicillin, and 100 μg/ml streptomycin (Invitrogen). Cells were incubated at 37 °C 
in 5% CO2-95% air atmosphere. DNA extraction was performed when cells were near-confluent monolayers and 
collected by using trypsin-EDTA solution.
Demethylation treatment. CS cell lines SW1353 and CS-1, seeded in 6-well plates at 5 × 105 cells per well, 
were allowed to attach overnight and then treated with demethylation drug 5-Aza-2′-deoxycytidine (5-Aza-dC, 
Sigma-Aldrich, MO, USA) dissolved in RPMI 1640 medium at 1, 5, and 10 μmol/L for 3 days. During the course 
of treatment, medium was changed every day with the same concentration of 5-Aza-dC. At the end of the treat-
ment period, cells were washed twice with PBS and harvested for western blot analysis.
Patient specimens and clinical data. The study and the consent of the informed patients were approved 
by the Partners Human Research Committee (number: 2007P-002464). All patients were informed and provided 
written consent that their information and the use of tissue samples stored in the databases of MGH Sarcoma 
Tumor Bank would be utilized for research. The information or images contained in the manuscript could not 
lead to identification of any study participant. All methods described in this manuscript were performed in 
accordance with the relevant guidelines and regulations by our institution. A retrospective study of 45 tumor 
specimens from 40 individual CS patients was evaluated by using the MGH Cancer Registry and the Orthopedic 
Oncology database. Histologic subtype and grade were scored by pathologists at MGH. The following patient data 
was collected: age, gender, histologic subtype, tumor grade, tumor location, metastatic status, recurrent status, 
disease status, and date of death (if applicable). The clinical data of CS patients are shown in Table 1.
DNA isolation. Extraction of DNA from CS cell lines SW1353, CS-1, and tumor tissues were performed 
using QIAamp DNA Micro kit (Qiagen, Valencia, CA). The extraction was carried out according to the manufac-
turer’s instructions. Briefly, CS tumor tissue samples or cell pellets from cultured cell lines, approximately 8 mg in 
weight, were transferred to a 1.5 mL microcentrifuge tube, and 180 µL of buffer ATL (Qiagen) were added imme-
diately. After equilibrating to room temperature (25 °C), 20 µL of proteinase K was added and cell were vortexed 
for 15 seconds. The sample tube was incubated at 56 °C overnight until the sample was completely lysed. The next 
day, 200 µL buffer AL (Qiagen) was added and cells were again vortexed for 15 seconds. Subsequently, 200 µL of 
ethanol (96–100%) were added. The mixture obtained was loaded on a QIAampMiniElute spin column provided 
by the kit and washed with AW1 buffer followed by AW2 buffer (Qiagen). DNA was eluted with 60 µL of buffer 
AE (Qiagen) and preserved at −20 °C until use.
Quantitative real-time PCR of WIF1 promoter methylation. The WIF1 promoter methylation lev-
els in CS cell lines and tumor tissues were determined by MethylScreen technology using the EpiTect Methyl 
II PCR Array (Qiagen). This study in CS cell lines used a 22 tumor suppressor gene panel that included WIF1 
(Supplementary Table 1). The method employed by the EpiTect Methyl II PCR System can distinguish methylated 
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from unmethylated sequences through methylation-sensitive (Ms) and/or methylation-dependent (Md) restric-
tion enzymes cleaving target CpG islands or not, rather than converting unmethylated CpG sites by bisulfite 
treatment. Following digestion, the remaining DNA of each digestion was quantified by real-time PCR. The rel-
ative fractions of methylated and unmethylated DNA were subsequently calculated by comparing the amount in 
each reaction with that of a mock (Mo, no enzymes added) reaction. Briefly, 1 μg or 125 ng genomic DNA was 
equally separated into four reactions, which were subsequently subjected to mock digestion, digestion of Ms or 
Md restriction endonuclease individually, or both (Msd). The amount of target promoter sequence in each reac-
tion was quantified by real-time PCR using primers with SYBR Green ROX Mastermix (Qiagen) and analyzed 
with a StepOnePlus Real-time PCR System (Applied Biosystems); all primers used in procedure are purchased 
from Qiagen. PCR cycling conditions were described as follows: 95 °C for 10 min, 3 cycles of 99 °C for 30 sec, 72 °C 
for 1 min, 40 cycles of 97 °C for 15 sec, 72 °C for 1 min with real-time signal acquisition. The melting curve was 
performed using the default program on the instrument after the cycling program.
WIF1 methylation analysis. Upon completion of real-time PCR, CT values were obtained by setting the 
threshold values and baseline as follows: 0.2 (threshold cell lines), 0.02 (threshold tissues), and 2–15 (baseline). 
The identical threshold and baseline are set for comparing multiple plates between CS cell lines or among CS 
tissue samples. This was repeated if the CT value did not pass the data quality control, which required the CT value 
of mock digest to be within the range of 18 to 27 cycles and the difference in CT value between Msd and mock to 
be greater than 3(ΔCT [Msd − mock] > 3). Subsequently, the methylation status was calculated by ΔCT method 
following manufacturer’s instruction. Due to the inversely proportional relationship between threshold cycle and 
the amount of input DNA, and due to the doubling of PCR product with every cycle in the exponential phase of 
the reaction, the initial DNA amount in each digest before PCR was expressed as:








The fraction of DNA in each digest was calculated by normalizing the DNA amount to the amount of digest-
ible DNA. The amount of digestible DNA was equal to the total amount of DNA (determined from the mock 
digest) minus the amount of DNA resistant to DNA digestion (determined from the double digest).
Hypermethylated (HM) DNA Fraction:
Clinical parameters Total N
WIF1 methylation 
level (%) 
[mean ± SE] P value
All cases 43 46.61 ± 6.09
Age (years) 0.072
 ≤45 21 36.25 ± 8.77
 >45 22 56.49 ± 8.09
Gender 0.895
 Male 30 45.21 ± 7.28
 Female 13 49.83 ± 11.50
Histologic Subtype 0.571
 Hyaline and/or 
Myxoid 21 45.32 ± 9.17
 Dedifferentiated 12 57.10 ± 9.56
 Mesenchymal 3 29.08 ± 29.04
 NOS 5 51.80 ± 21.54
Grade 0.195
 1 10 28.68 ± 12.79
 2 23 46.99 ± 8.59
 3 9 68.44 ± 9.62
Metastatic 0.358
 Present 10 55.69 ± 12.86
 Absent 33 43.86 ± 6.95
Recurrent 0.267
 Present 12 36.16 ± 12.70
 Absent 31 50.65 ± 6.87
Location 0.237
 Limbs 25 40.33 ± 8.00
 Trunk 18 55.32 ± 9.26
Table 1. Status of WIF1 methylation in CS tissue and their relations to clinical parameters. SE represents 
standard error; NOS represents not otherwise specified.
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Intermediately methylated (IM) DNA fraction:
= − −F 1 F F (4)IM HM UM
Methylated (M) DNA fraction:
= +F F F (5)M HM IM
Results of gene methylation were presented as the percentage unmethylated and methylated fraction of input 
DNA; methylated indicates the fraction of input genomic DNA containing two or more methylated CpG sites in 
the promoter of a targeted gene.
Western blot. Total protein was isolated from CS-1 and SW1353 cells with 1 × RIPA lysis buffer (Upstate 
Biotechnology, Charlottesville, VA) supplemented with complete protease inhibitor cocktail tablets (Roche 
Applied Science, IN, USA). Protein concentrations were examined by Protein Assay Reagents (Bio-Rad, Hercules, 
USA). Equal amounts of denatured proteins were separated by NuPAGE® 4–12% Bis-Tris Gel (Life Technologies) 
and transferred onto a nitrocellulose membrane (Bio-Rad). After blocking in 5% non-fat milk for two hours, the 
membranes were incubated with specific primary antibodies WIF1 (Cell Signaling Technology, catalog number: 
5652, 1:1000 dilution), Wnt5a/b (Cell Signaling Technology, catalog number: 2530, 1:1000 dilution), LRP6 (Cell 
Signaling Technology, catalog number: 3395, 1:1000 dilution), Dvl2 (Cell Signaling Technology, catalog number: 
3224, 1:1000 dilution), and β-Actin (Sigma-Aldrich, dilution 1:2000) at 4 °C overnight. The membranes were 
further probed with respective secondary antibodies (LI-COR Biosciences, NE, USA), and scanned by Odyssey® 
CLx equipment (LI-COR Biosciences, NE, USA) to detect the bands and the density.
Statistical analysis. All statistical analyses were carried out using SPSS 17.0 software (Chicago, IL). We 
confirmed continuous variables were not within normal distribution by using the Shapiro-Wilk test. Then the 
Wilcoxon analysis and Kruskal-Wallis test were used to compare methylation levels between groups, sorted by 
age, gender, metastatic, recurrent, grade, histologic subtype, and location. Kaplan-Meier survival curves were 
generated to determine the relationship between the methylation levels of WIF1 and patient prognosis, and 
the log-rank test was applied to detect the difference between survival curves. Cox proportional hazard regres-
sion model was used to estimate the effect on survival outcomes of histologic subtype, grade, metastatic status, 
recurrent situation, tumor location, and DNA methylation level. Multivariate analysis was performed by the Cox 
proportional hazard method with the inclusion of all the variables taken into account for univariate analysis. 
Overall survival (OS) time was calculated from the date of tumor diagnosis to the date of death or last follow-up. 
Progression-free survival (PFS) time was calculated from the date of tumor diagnosis to the date of death or 
occurring metastasis and/or recurrence. All p-values were two-sided and p < 0.05 was considered as statistically 
significant.
Results
Identification of WIF1 promoter methylation in CS cell lines. We examined the methylation levels 
of WIF1 promoter (Fig. 1A) in CS cell lines CS-1 and SW1353. The WIF1 gene was chosen for this study because 
of its known involvement in regulating tumorogenesis in various cancers, but had not yet been studied in CS 
(Supplementary Table 1). Representative amplification curves of WIF1 in two cell lines are showed in Fig. 1B. We 
found 97.33% of WIF1 promoters were methylated in CS-1 and 96.22% in SW1353, respectively (Fig. 1C). The 
methylation levels of 22 genes range from 0.51% to 98.81% in CS-1 and from 0.05% to 99.61% in SW1353.
DNA methylation can silence WIF1 expression and increase Wnt signaling in human CS cell 
lines. Since WIF1 showed promoter methylation in CS cell lines, Western blot analysis was used to further 
determine the protein expression of WIF1. As expected, WIF1 exhibited loss of expression in both CS cell lines 
CS-1 and SW1353 (Fig. 2, Supplementary Figure S1). After treatment with methylation inhibitor 5-Aza-dC for 
the demethylation process, the expression of WIF1 was restored (Fig. 2, Supplementary Figure S1). Quantitative 
analysis of Western blot data showed that 5-Aza-dC enhanced WIF1 expression in a dose-dependent manner. 
In addition, we further analyzed WIF1 mediated Wnt signaling pathways in CS. Results demonstrated that 
demethylation of WIF1 led to a decreased expression of Wnt5a/b, LRP6, and Dvl2 in our CS cell lines (Fig. 2, 
Supplementary Figure S2). Taken together, these results suggest that DNA methylation of WIF1 can activate the 
Wnt pathway in CS.
WIF1 promoter methylation level in CS patient tissues and its association with clinical 
data. We further examined the methylation levels of WIF1 in 45 tumor specimens of patients with CS. Two 
of the 45 cases were excluded since their CT values did not pass quality control (after repeating three times). The 
WIF1 methylation level in 43 CS tissue samples were distributed as follows: mean 46.61; median 60.13; standard 
deviation (SD) 39.92; range 0.00–99.54 (Fig. 3A). Methylation of promoter CpG islands was detected in 19 cases 
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(44%) for levels between 0% to 25%, two cases (5%) for 26% to 50%, nine cases (21%) for 51% to 75%, and 13 
cases (30%) for 76% to 100% (Fig. 3B). Median age at diagnosis was 47 years (range 21–80), and sex ratio (male/
female) was 2.3:1 (30 vs. 13). Ten cases (23%) had metastatic disease and 12 cases (39%) were recurrent. We then 
analyzed the relationship between the WIF1 methylation level and various clinical variables. Among the cases 
classified by histologic subtype, one case ‘Diffuse large cell Lymphoma’ and one case ‘Juxtacortical’ were excluded 
since the case number was too small for statistical analysis. Across the cases classified by grade, one case was 
excluded because the grade of the tumor was unavailable. A weak correlation between WIF1 methylation level 
and age (p = 0.072) was observed but was not statistically significant (Table 1). Importantly, none of the clinical 
parameters (gender, histologic subtype, grade, metastatic status, recurrent status, and location) of CS were signif-
icantly correlated with WIF1 methylation level (Table 1).
WIF1 methylation level and patient survival. We assessed the association of WIF1 methylation level 
with survival outcomes. Among 43 cases of CS, 17 of them (40%) had died of disease within a median follow-up 
period of 25 months; mean period of total follow-up time was 57.63 months (range from 1 to 234 months). Based 
on the methylation level of patient samples, we categorized all cases into four quartiles as previous describe 
(Q1: ≥87.17%; Q2: 60.13–87.17%; Q3: 2.49–60.13%; Q4: <2.49%)33, 34. The Kaplan-Meier analysis showed that 
overall survival was significantly different among the four groups (log-rank p < 0.05); however, progression-free 
survival was not significantly different across the four groups (log-rank p = 0.094) (Fig. 4). Q1 was defined 
as the “high-methylation-level group” and Q2, Q3, and Q4 were combined into the “low-methylation-level 
group”33. The survival time of the “high-methylation-level group” was significantly shorter than that of the 
“low-methylation-level group” for overall survival and progression-free survival (log-rank p < 0.05) (Fig. 4). The 
median survival times for overall and progression-free in each group are shown in Table 2.
Figure 1. (A) The location of the CpG island in the WIF1 promoter. The target CpG island is located in Chr12: 
65514878–65515863. (B) Representative amplification plots from real-time PCR of WIF1 in CS cell lines. Yellow 
curve (Legend B) indicates group Mo, which was subjected to no enzyme and represents the total amount of 
input DNA; Green curve (Legend D) indicates group Ms, which was subjected to methylation-sensitive enzyme 
and represents DNA in which all CpG sites are methylated; Blue curve (Legend F) indicates group Md, which 
was subjected to methylation-dependent enzyme and represents unmethylated DNA; Pink curve (Legend H) 
indicates group Msd, which was subjected to both methylation-sensitive and methylation-dependent enzyme 
and represents DNA refractory to enzyme digestion (background signal). The X-axis shows the cycle number 
of real-time PCR, and Y-axis shows fluorescence intensity. (C) Methylation profile of WIF1 in CS cell lines. The 
methylation event of the promoter in WIF1 is high frequency in CS cell lines CS-1 (M, 97.33%; UM, 2.67%) and 
SW1353 (M, 96.22%; UM, 3.78%). M represents methylation, UM represents unmethylated.
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Next, we confirmed the above observations using univariate Cox analysis (Table 3, Table 4). In addition, his-
tologic subtype, and metastatic status were found to be significantly associated with patient survival for overall 
survival (p < 0.05). In further study of multivariate Cox analysis, we found that the WIF1 methylation level was an 
independent prognostic factor in CS. Overall survival and progression-free survival were significantly shorter in 
the “high-methylation-level group” than in the “low-methylation-level group” (p < 0.05). The hazard rates (HR) 
for overall survival and progression-free survival were 2.893 (95%CI: 1.167–7.170) and 2.399 (95%CI: 1.020–
5.641), respectively. Moreover, histologic subtype and metastatic status were found to be significantly related with 
patient survival for overall survival and histologic subtype was also significantly associated with patient outcome 
for progression-free survival (Table 3, Table 4).
Figure 2. Epigenetic silencing of WIF1 derepresses Wnt signaling. (A) In CS cell line SW1353, Western blot 
analysis showed a trend induction of WIF1 expression after treatment with 1, 5, 10 μM 5-Aza-dC for 3 days. 
Wnt components including Wnt5a/b, Dvl2, and LRP6 were simultaneously suppressed with gradually restored 
WIF1 protein level. (B) In CS cell line CS-1, WIF1 was downregulated but re-expressed after reversion of 
DNA methylation. A notable repression of Wnt signaling (Wnt5a/b, Dvl2, and LRP6) was exhibited after the 
activation of WIF1. Western blot images were cropped to improve the clarity and conciseness of the result; 
samples derive from the same blots were processed in parallel.
Figure 3. Methylation level of WIF1 in CS patient tissues. (A) Methylation levels of WIF1 in each specimen are 
presented. (B) Distributions are shown for 43 CS tumor samples.
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Discussion
We have demonstrated for the first time WIF1 promoter methylation in CS cell lines CS-1 and SW1353. Western 
blot results showed that there was a silencing of WIF1 in CS cells. We also observed an upregulation of WIF1 
expression after exposure to a demethylation agent. Our data suggests that WIF1 promoter methylation is an 
important epigenetic mechanism leading to WIF1 downregulation in CS. In osteosarcoma, WIF1 silencing due 
to promoter methylation has been recognized to facilitate tumor proliferation, migration, and lung metastasis in 
vivo and in vitro20, 21. Considering this, we assume that aberrant methylation of WIF1 is a vital factor affecting Wnt 
function and downstream signaling in CS.
Figure 4. Kaplan-Meier curves of overall survival and progression-free survival of different quartiles of WIF1 
methylation level in CS. (A) Kaplan-Meier curves of OS showed a significant difference across the Q1, Q2, 
Q3, and Q4 groups (p = 0.016). (B) Kaplan-Meier curves of PFS showed a weak difference among these four 
groups, but was not significant (p = 0.094). (C) OS of Q1 group was significantly shorter than the Q2–4 group 
(p = 0.008). (D) PFS of Q1 group was significantly shorter than the Q2–4 group (p = 0.023). Q1 represents the 
“high-methylation-level group” and Q2, Q3, and Q4 collectively represent the “low-methylation-level group”.
Group
Overall Survival Progression-free Survival
Estimate SE CI Estimate SE CI
Q1 25.000 11.034 3.373–46.627 25.000 11.034 3.373–46.627
Q2–4 53.000 18.081 17.561–88.439 50.000 19.402 11.972–88.028
Overall 36.000 11.322 13.810–58.190 36.000 11.604 13.255–58.745
Table 2. Medians (months) for OS and PFS. SE represents standard error; CI represents confidence interval; Q1 
represents the “high-methylation-level group”; Q2–4 represent the “low-methylation-level group”.
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Previous reports have demonstrated that activation of the Wnt pathway exists in CS cells and primary CS 
tissue27–29. Regarding the close relationship between Wnt signaling and WIF1, we performed further experiments 
to verify whether the Wnt pathway was involved in the inhibitory effect of WIF1.
LRP6, an indispensable co-receptor for the Wnt signaling pathway, has been found highly expressed in sev-
eral human cancer cell lines and human malignant tissues35. In agreement with this report, our data showed that 
LRP6 was highly expressed in CS cells. Importantly, LRP6 was simultaneously reduced with gradual restoration 
of WIF1 expression. Moreover, recent work reported that Dvl2 was overexpressed in prostate cancer cell lines and 
tissues and its silencing by RNAi can reduce cell proliferation and migration36. Likewise, we demonstrated an ele-
vated protein level of Dvl2 in CS cell lines, but a diminished level after WIF1 recovery. Another Wnt component, 
Wnt5a/b, was found to be overexpressed and involved in the migration of Ewing sarcoma37. Similarly, there is also 
a notable expression of Wnt5a/b and an inverse correlation between the expression of Wnt5a/b and WIF1. Taken 
together, our results support the hypothesis that WIF1 restoration could attenuate the activity of Wnt pathway 
and impedes the transmission of Wnt signal.
Parameters
Univariate analysis Multivariate analysis
HR CI P value HR CI P value
Age (discrete variable) 1.023 0.997–1.049 0.078 … … …
Gender (female as 
reference) 1.563 0.658–3.710 0.312 … … …
WIF1 methylation level 
(Q2–4 as reference) 2.980 1.268–7.003 0.012 2.893 1.167–7.170 0.022*
Histologic Subtype 
(Hyaline and/or Myxoid 
as reference)
… … 0.007 … … 0.002*
 NOS 1.524 0.427–5.446 0.517 0.921 0.243–3.487 0.903
 Dedifferentiated 4.753 1.930–11.705 0.001 5.881 2.277–15.187 0.000*
 Mesenchymal 1.188 0.265–5.334 0.822 1.052 0.231–4.779 0.948
Grade (1 as reference) … … 0.111 … … …
 2 2.164 0.781–5.999 0.138 … … …
 3 3.431 1.081–10.887 0.036 … … …
Metastatic (Absent as 
refernece) 2.972 1.245–7.094 0.014 2.926 1.163–7.359 0.023*
Recurrent (Absent as 
reference) 0.623 0.262–1.482 0.284 … … …
Location (Limbs as 
reference) 1.141 0.533–2.444 0.734 … … …
Table 3. Univariate and multivariate analysis of overall survival by Cox proportional hazard regression model. 
… represents “data not available”; * represents p < 0.05; Abbreviations: HR, hazard ratio; CI, confidence 
interval; NOS, not otherwise specified.
Parameters
Univariate analysis Multivariate analysis
HR CI P value HR CI P value
Age (discrete variable) 1.019 0.996–1.042 0.110 … … …
Gender (female as 
reference) 1.317 0.623–2.786 0.471 … … …
WIF1 methylation level 
(Q2–4 as reference) 2.492 1.093–5.682 0.030 2.399 1.020–5.641 0.045*
Histologic Subtype 
(Hyaline and/or Myxoid as 
reference)
… … 0.047 … … 0.048*
 NOS 2.070 0.747–5.738 0.162 1.622 0.564–4.666 0.369
 Dedifferentiated 3.110 1.348–7.171 0.008 3.213 1.384–7.460 0.007*
 Mesenchymal 0.944 0.216–4.132 0.939 0.895 0.204–3.934 0.884
Grade (1 as reference) … … 0.135 … … …
 2 2.466 0.982–6.195 0.055 … … …
 3 2.531 0.841–7.613 0.098 … … …
Location (Limbs as 
reference) 1.284 0.642–2.565 0.480 … … …
Table 4. Univariate and multivariate analysis of progression-free survival by cox proportional hazards 
regression model. … represents “data not available”; * represents P < 0.05; Abbreviations: HR, hazard ratio; CI, 
confidence interval; NOS, not otherwise specified.
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Recently, preclinical work has focused on targeting Wnt signaling as a potential therapy. For example, LRP6 
knockdown by shRNA in breast cancer cells can reduce cell proliferation and administration of LRP6 inhibitor, 
Mesd, is able to suppress tumor growth in vivo38. Overexpression of Wnt5a in melanoma correlates with chem-
otherapeutic resistance39. In this regard, a novel therapeutic strategy could be developed to inhibit Wnt compo-
nents, including LRP6, Dvl2, and Wnt5a/b through restoration of WIF1 expression.
The prognosis of CS has been related to various clinical parameters, such as histological grade, age, tumor size, 
and positive/negative surgery margin. Biomolecular markers, including RUNX3 promoter methylation, have also 
been associated with patient outcome15, 40, 41. It has also been shown that activation of Wnt signaling is associated 
with negative CS patient outcome42. However, the relationship between WIF1 methylation level and the progno-
sis of CS has not been demonstrated. Our data indicates that patients with higher WIF1 methylation levels have 
poorer overall survival and progression-free survival rates as compared with the WIF1 low-level group. This sug-
gests that the WIF1 methylation level could be an independent prognostic factor for overall and progression-free 
survival. These findings explore a new prognostic marker in patients with CS. Additionally, histologic subtype, 
especially dedifferentiated CS, was also shown to contribute to a poorer outcome with the highest hazard rate 
compared with other factors. This is consistent with previous studies and clinical experience6, 11. Of note, regard-
ing the limited publications of CS that are mainly composed of case reports or small case series, we found few 
studies that included more than 40 patients with relative long term follow-up data41, 43–45. For example, one meth-
ylation study focused on RUNX3 in CS patients with a total follow-up time of 5 years and an epigenetics study on 
microRNA-494 in CS patients again with a 5 year follow-up8, 15.
In a 44 case lung cancer study, WIF1 methylated patients had an inferior overall survival and multivariate 
analysis revealed WIF1 methylation was an independent prognostic factor in overall survival46. Interestingly, 
methylation of WIF1 has been demonstrated as an independent outcome predictor with a negative impact on 
patient prognosis in different cancers, including leukemia, lung cancer, breast cancer, and colon cancer47–50. 
Taken together, WIF1 methylation may be a common event in malignancies, and anti-methylation of WIF1 may 
improve patient survival and serve as a potential treatment in cancers, including in CS. Recent work has provided 
preclinical evidence that isoliquiritigenin treatment can prevent breast cancer initiation and progression through 
WIF1 demethylation51. In human non-small cell lung cancer, norcantharidin treatment was found to inhibit 
tumor cell proliferation and invasion by promoting WIF1 demethylation52. This is attractive as it may expand the 
activity of these agents in clinic. In this regard, it sheds novel light on selectively reversing epigenetic changes of 
WIF1 for CS prevention and a unique targeted strategy could emerge. Thus, although the mechanism of WIF1 
methylation need to be further clarified, our work may contribute to an improvement in survival rate for patients 
with CS.
We next explored the WIF1 methylation level in CS patient tissues and analyzed the potential association 
of WIF1 methylation with other clinical parameters by performing statistical analysis. However, no significant 
associations were found. A larger scale study may be necessary to uncover any associations of WIF1 methylation 
with clinical parameters.
In summary, we show that absent expression of WIF1 is due to its high-frequency methylation in CS cell lines 
and confirmed an aberrant activation of Wnt signaling via WIF1 silencing. High methylation level of WIF1 was 
associated with both shortened progression-free and overall survival in patients with CS. These data suggest that 
WIF1 methylation is a promising prognostic predictor in patients with CS. Further study of the mechanisms 
of WIF1 may provide innovative therapeutic strategies in the treatment of CS focusing on the Wnt signaling 
pathway.
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